S'abonner

Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69?CD56dim cells - 19/04/17

Doi : 10.1016/j.jaci.2016.07.043 
Nicole Marquardt, PhD a, Eliisa Kekäläinen, MD, PhD a, Puran Chen, MD a, Egle Kvedaraite, MD a, Jennifer N. Wilson, BSc a, Martin A. Ivarsson, PhD a, Jenny Mjösberg, PhD a, Lena Berglin, PhD a, Jesper Säfholm, PhD b, Martijn L. Manson, PharmD, PhD b, d, Mikael Adner, PhD b, Mamdoh Al-Ameri, MD c, Per Bergman, MD, PhD c, Ann-Charlotte Orre, MD c, Mattias Svensson, PhD a, Barbro Dahlén, MD, PhD b, Sven-Erik Dahlén, MD, PhD b, Hans-Gustaf Ljunggren, MD, PhD a, Jakob Michaëlsson, PhD a,
a Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 
c Thoracic Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 
b Unit for Experimental Asthma and Allergy Research, Centre for Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 
d Respiratory, Inflammation and Autoimmunity (RIA), Innovative Medicines, Astra Zeneca R&D, Gothenburg, Sweden 

Corresponding author: Jakob Michaëlsson, PhD, Center for Infectious Medicine, F59. Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden.Center for Infectious MedicineF59. Karolinska InstitutetKarolinska University HospitalStockholm141 86Sweden

Abstract

Background

In contrast to the extensive knowledge about human natural killer (NK) cells in peripheral blood, relatively little is known about NK cells in the human lung. Knowledge about the composition, differentiation, and function of human lung NK cells is critical to better understand their role in diseases affecting the lung, including asthma, chronic obstructive pulmonary disease, infections, and cancer.

Objective

We sought to analyze and compare the phenotypic and functional characteristics of NK cells in the human lung and peripheral blood at the single-cell level.

Methods

NK cells in human lung tissue and matched peripheral blood from 132 subjects were analyzed by using 16-color flow cytometry and confocal microscopy.

Results

CD56dimCD16+ NK cells made up the vast majority of NK cells in human lungs, had a more differentiated phenotype, and more frequently expressed educating killer cell immunoglobulin-like receptors compared with NK cells in peripheral blood. Despite this, human lung NK cells were hyporesponsive toward target cell stimulation, even after priming with IFN-α. Furthermore, we detected a small subset of NK cells expressing CD69, a marker of tissue residency. These CD69+ NK cells in the lung consisted predominantly of immature CD56brightCD16 NK cells and less differentiated CD56dimCD16+ NK cells.

Conclusion

Here, we characterize the major NK cell populations in the human lung. Our data suggest a model in which the majority of NK cells in the human lung dynamically move between blood and the lung rather than residing in the lung as bona fide tissue-resident CD69+ NK cells.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Natural killer cells, innate lymphoid cells, lung, differentiation, killer cell immunoglobulin-like receptor, CD69, tissue residency

Abbreviations used : ADCC, COPD, Eomes, FITC, ILC, KIR, NK, NKG, PE


Plan


 Supported by the Swedish Medical Research Council, the Strategic Research Foundation, the Swedish Cancer Society, the German Research Foundation (Grant MA-5449/1-1), the Swedish Heart-Lung Foundation, the Stockholm County Research Funds (ALF), the Karolinska Institutet Foundations, and the AZ Translational Medicine unconditional grant for the ChAMP project.
 Disclosure of potential conflict of interest: N. Marquardt has received a grant from the German Research Foundation (DFG). E. Kekäläinen has received grants from the Finnish Medical Foundation, Foundation for Pediatric Research Finland, Emil Aaltonen Foundation, Orion Research Foundation, Maud Kuistila Memory Foundation, Sigrid Jusélius Fellowship, Foundation of the Finnish Anti-Tuberculosis Association, and Jalmari and Rauha Ahokas Foundation. J. Mjösberg has received a grant from the Swedish Foundation for Medical Research (SSMF) and has consultant arrangements with ONO Pharmaceutical. M. L. Manson is employed by AstraZeneca. B. Dahlén has received grants from the Swedish Heart Lung Foundation, Swedish MRC, Stockholm County Council, Swedish Asthma and Allergy Association's Research Foundation, and Centre for Allergy Research, Karolinska Institutet; has consultant arrangements with Teva; and has received payment for lectures from the Swedish Food and Drug Regulatory Agency. S.-E. Dahlén has received grants from the Swedish MRC, Heart-Lung Foundation, Strategic Research Foundation, and ChAMP and has board memberships and consultant arrangements with AstraZeneca, GlaxoSmithKline, and RSPR AB. H.-G. Ljunggren has received grants from the Swedish Research Council, Swedish Cancer Society, and Swedish Foundation for Strategic Research. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 139 - N° 4

P. 1321 - avril 2017 Retour au numéro
Article précédent Article précédent
  • Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study
  • Karoline Krause, Athanasios Tsianakas, Nicola Wagner, Jörg Fischer, Karsten Weller, Martin Metz, Martin K. Church, Marcus Maurer
| Article suivant Article suivant
  • Inducible and naturally occurring regulatory T cells enhance lung allergic responses through divergent transcriptional pathways
  • Anthony Joetham, Michaela Schedel, Brian P. O'Connor, Soohyun Kim, Katsuyuki Takeda, Jordan Abbott, Erwin W. Gelfand

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.